Nevada (State of Incorporation) |
001-13305 (Commission File Number) |
95-3872914 (IRS Employer Identification Number) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. | ||||||||
Item 9.01 Financial Statements and Exhibits | ||||||||
SIGNATURES | ||||||||
EXHIBIT INDEX | ||||||||
EXHIBIT 99.1 |
Item 5.02 | Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. |
Item 9.01 | Financial Statements and Exhibits |
d. | Exhibits: |
Ex. 99.1 | Press release titled Watson Pharmaceuticals Announces Appointment of Andrew L. Turner as Chairman of the Board of Directors Allen Chao, Ph.D., to Resign from the Board of Directors dated May 12, 2008 |
Date: May 12, 2008 | By: | /s/ David A. Buchen | ||
David A. Buchen | ||||
Senior Vice President, General Counsel and Secretary |